Ad
related to: lutetium 177 radiation safety- Sign Up for Updates
Sign up to receive the latest data,
case studies, and resources.
- Contact Us
Contact our representatives
for product and reimbursement info.
- Find an Imaging Site
Locate the nearest imaging site
or contact customer service.
- Case Studies
Review real case studies
with real patients.
- Sign Up for Updates
Search results
Results from the WOW.Com Content Network
Lutetium (177 Lu) oxodotreotide or 177 Lu dotatate, brand name Lutathera, is a chelated complex of a radioisotope of the element lutetium with dotatate, used in peptide receptor radionuclide therapy. Specifically, it is used in the treatment of cancers which express somatostatin receptors. [5] It is a radiolabeled somatostatin analog. [3] [6] [7]
Lutetium (177 Lu) chloride is a radioactive compound used for the radiolabeling of pharmaceutical molecules, aimed either as an anti-cancer therapy or for scintigraphy (medical imaging). [ 5 ] [ 6 ] It is an isotopomer of lutetium(III) chloride containing the radioactive isotope 177 Lu , which undergoes beta decay with a half-life of 6.64 days.
Lutetium (177 Lu) vipivotide tetraxetan, sold under the brand name Pluvicto, is a radiopharmaceutical medication used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). [5] [6] Lutetium (177 Lu) vipivotide tetraxetan is a targeted radioligand therapy. [6] [8]
Radiation from lutetium (177 Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney. [45] Arginine/lysine can be used to reduce renal radiation exposure during peptide receptor radionuclide therapy with lutetium ( 177 Lu) oxodotreotide.
Under the renewed licensing agreement, ITM grants NTP the use of intellectual property (IP) rights related to the manufacturing of n.c.a. 177 Lu. ITM is a global leading producer and supplier of n.c.a. 177 Lu, a medical radioisotope frequently used in Radiopharmaceutical Therapy (RPT) for the treatment of cancer. ITM’s expertise will support ...
Lutetium-177, a radioisotope that can be derived from lutetium(III) chloride, is used in targeted cancer therapies. [8] When lutetium-177 is attached to molecules that specifically target cancer cells, it can deliver localized radiation to destroy those cells while sparing surrounding healthy tissue. [9]
Forty radioisotopes have been characterized, with the most stable, besides 176 Lu, being 174 Lu with a half-life of 3.31 years, and 173 Lu with a half-life of 1.37 years. All of the remaining radioactive isotopes have half-lives that are less than 9 days, and the majority of these have half-lives that are less than half an hour.
As of 2016 it was under development by the Norwegian company Nordic Nanovector ASA as a radioimmunotherapeutic in which lilotomab is conjugated to the beta radiation-emitting isotope lutetium-177 by means of a linker called satetraxetan, a derivative of DOTA. [2]
Ad
related to: lutetium 177 radiation safety